Meclizine Hydrochloride Tablets, Usp

Meclizine Hydrochloride Tablets, Usp
SPL v6
SPL
SPL Set ID f574e123-8db7-4e3d-a0ee-e4e1f04ff146
Route
ORAL
Published
Effective Date 2022-06-01
Document Type 34391-3 HUMAN PRESCRIPTION DRUG LABEL

Drug Facts

Composition & Product

Active Ingredients
Meclizine (25 mg)
Inactive Ingredients
Silicon Dioxide Croscarmellose Sodium Lactose Monohydrate Magnesium Stearate Microcrystalline Cellulose D&c Yellow No. 10 Aluminum Oxide

Identifiers & Packaging

Pill Appearance
Imprint: TL121 Shape: oval Color: yellow Size: 13 mm Score: 2
Marketing Status
ANDA Active Since 2010-06-04

Description

Chemically, Meclizine HCl is 1-( p -chloro-α-phenylbenzyl)-4-( m -methylbenzyl) piperazine dihydrochloride monohydrate.                           C 25 H 27 ClN 2 . 2HCl . H 2 O                                                                                        M . W . 481 . 88 Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

Indications and Usage

For the management of nausea and vomiting, and dizziness associated with motion sickness.

Dosage and Administration

Motion Sickness The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Contraindications

Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

Adverse Reactions

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

How Supplied

Meclizine HCI Tablets, USP are available in the following strengths and package sizes: 25 mg (Yellow, oval-shaped, scored, debossed with TL121) Bottles of 10 NDC 63187-996-10 Bottles of 20            NDC 63187-996-20 Bottles of 30            NDC 63187-996-30 Bottles of 60            NDC 63187-996-60 Bottles of 90            NDC 63187-996-90 Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature]. Manufactured By: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA. Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320 Revised 03/11


Medication Information

Indications and Usage

For the management of nausea and vomiting, and dizziness associated with motion sickness.

Dosage and Administration

Motion Sickness

The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Contraindications

Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

Adverse Reactions

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

How Supplied

Meclizine HCI Tablets, USP are available in the following strengths and package sizes:





25 mg (Yellow, oval-shaped, scored, debossed with TL121)



Bottles of 10 NDC 63187-996-10

Bottles of 20            NDC 63187-996-20

Bottles of 30            NDC 63187-996-30

Bottles of 60            NDC 63187-996-60

Bottles of 90            NDC 63187-996-90



Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].

Manufactured By:



Jubilant Cadista Pharmaceuticals Inc.

Salisbury, MD 21801, USA.

Repackaged by:

Proficient Rx LP

Thousand Oaks, CA 91320

Revised 03/11

Description

Chemically, Meclizine HCl is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.

                          C25H27ClN2 . 2HCl. H2O                                                                                        M.W. 481.88



Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

Warnings

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.



Patients should avoid alcoholic beverages while taking this drug.



Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.

Precautions

PREGNANCY, Teratogenic Effects

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary. 



Pediatric Use

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

Clinical Pharmacology

Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Principal Display Panel

NDC 63187-996-20



Meclizine Hydrochloride Tablets, USP



25 mg





20 Tablets



Rx Only



Each tablet Contains 25 mg of meclizine HCl



DOSAGE AND USE 

See accompanying prescribing information



MOTION SICKNESS:

25 mg to 50 mg daily.



Dispense in tight, light-resistant containers (USP).



Store at 20-25°C (68-77°F)

[See USP Controlled Room Temperature].


Structured Label Content

Warnings (WARNINGS)

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.



Patients should avoid alcoholic beverages while taking this drug.



Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.

Description (DESCRIPTION)

Chemically, Meclizine HCl is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.

                          C25H27ClN2 . 2HCl. H2O                                                                                        M.W. 481.88



Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

Precautions (PRECAUTIONS)

PREGNANCY, Teratogenic Effects

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary. 



Pediatric Use

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

How Supplied (HOW SUPPLIED)

Meclizine HCI Tablets, USP are available in the following strengths and package sizes:





25 mg (Yellow, oval-shaped, scored, debossed with TL121)



Bottles of 10 NDC 63187-996-10

Bottles of 20            NDC 63187-996-20

Bottles of 30            NDC 63187-996-30

Bottles of 60            NDC 63187-996-60

Bottles of 90            NDC 63187-996-90



Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].

Manufactured By:



Jubilant Cadista Pharmaceuticals Inc.

Salisbury, MD 21801, USA.

Repackaged by:

Proficient Rx LP

Thousand Oaks, CA 91320

Revised 03/11

Adverse Reactions (ADVERSE REACTIONS)

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

Contraindications (CONTRAINDICATIONS)

Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

Clinical Pharmacology (CLINICAL PHARMACOLOGY)

Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Indications and Usage (INDICATIONS AND USAGE)

For the management of nausea and vomiting, and dizziness associated with motion sickness.

Principal Display Panel (PRINCIPAL DISPLAY PANEL)

NDC 63187-996-20



Meclizine Hydrochloride Tablets, USP



25 mg





20 Tablets



Rx Only



Each tablet Contains 25 mg of meclizine HCl



DOSAGE AND USE 

See accompanying prescribing information



MOTION SICKNESS:

25 mg to 50 mg daily.



Dispense in tight, light-resistant containers (USP).



Store at 20-25°C (68-77°F)

[See USP Controlled Room Temperature].

Dosage and Administration (DOSAGE AND ADMINISTRATION)

Motion Sickness

The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.


Advanced Ingredient Data


Raw Label Data

All Sections (JSON)